Loading...
Not a good buy right now for an impatient entry. TBN is in a strong uptrend, but it’s currently extended/overbought (RSI_6 77.7) and trading just below a nearby resistance zone (30.31). With no Intellectia buy signals today and no fresh news catalyst, the risk/reward favors waiting for a pullback closer to ~28.46 (pivot) rather than buying at ~29.94 post-market.
Trend is bullish: SMA_5 > SMA_20 > SMA_200 confirms a strong upward structure. Momentum is also positive with an expanding MACD histogram (0.243 > 0), suggesting buyers remain in control. However, RSI_6 at 77.693 indicates the stock is stretched (overbought/extended), which often coincides with weaker immediate upside and higher odds of a short-term pullback. Key levels: Pivot support ~28.46 (near-term line in the sand), S1 ~26.61; resistance R1 ~30.31 then R2 ~31.45. At ~29.94, price is close to R1, meaning upside is likely capped unless it breaks and holds above ~30.31.
Intellectia Proprietary Trading Signals
Pattern-based probability (similar candlesticks) shows modest positive drift (next day +1.34%, next week +2.04%, next month +5.4%), but current positioning near resistance and elevated RSI makes the immediate entry less attractive.
and highlights large undeveloped acreage exposure in the Beetaloo Basin.
on 2026-02-11 after hours could act as a catalyst if progress/updates exceed expectations.
increases odds of near-term consolidation or pullback.
Latest reported quarter: 2026/Q1. Revenue remained effectively 0 (0.00% YoY), consistent with a pre/early-revenue phase. Net income improved to -8.182M (loss narrowed; +38.81% YoY improvement), and EPS improved to -0.47 (+11.90% YoY). Overall: losses are narrowing, but the company is still not demonstrating operating revenue yet—progress is more about development execution than sales growth at this stage. Next earnings on the calendar: QDEC 2025 results due 2026-02-11 after hours (EPS est. -0.33).
Recent trend: coverage initiation (single data point). On 2025-12-02, Wells Fargo initiated with Overweight and a $35 price target. Wall Street pro view (based on provided data): Pros—large prospective acreage position in an undeveloped basin and a staged development valuation framework supports upside. Cons—limited breadth of analyst coverage in the provided data and a pre-revenue/loss-making profile means the thesis relies heavily on development milestones and sentiment rather than proven cash flows.